Search This Blog

Wednesday, October 29, 2025

Lilly, Walmart in 1st Retail Pick-Up Option With DTC Pricing for Zepbound

 

  • Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect’s self-pay single-dose vials
  • Strategic collaboration marks the first time patients using LillyDirect, Lilly’s direct-to-consumer healthcare platform can access self-pay pricing for Zepbound vials at a retail pharmacy location
  • LillyDirect pick-up option at Walmart offers millions of Americans living with obesity additional convenience, access and choice in how they get their medication

Eli Lilly and Company (NYSE: LLY) and Walmart Inc. (NYSE: WMT) today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound® (tirzepatide) single-dose vials available through LillyDirect. Zepbound (ZEHP-bownd) vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November. LillyDirect’s direct-to-consumer pricing, or self-pay pricing, offers a 50 percent or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity.

A Walmart pharmacy counter with multiple service windows and customers waiting for assistance. The setting is a well-lit retail store with visible signage reading 'PHARMACY' in bold blue letters. Shelves stocked with medications and supplies are visible in the background.

Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay. Patients with a valid, on-label prescription can access Zepbound vials directly without using insurance. The collaboration with Walmart expands convenient access to Zepbound, especially for those who prefer the ease of pickup at their local Walmart pharmacy.


Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off, moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.